


# PROGESTERONE IN ASSISTED REPRODUCTION

Mina Jafarabadi- M.D.

Tehran University of Medical Sciences

# Progestogens




**Progesterone** (Prometrium, Utrogestan): **natural progestogen** produced in the body, or produced from a plant source but still chemically and structurally identical to human progesterone, and it is therefore referred to as “**bioidentical**” or “**natural**”.

**Progestin**: Gestagen; Gestogen; **synthetic progestogen**  
**Progesterone receptor agonist**

# Grouping

- Progestins are sometimes grouped in "generations," which refer to how long they have been on the market.
- To understand their effects is to group them by structure based on the hormone from which they were created

# PROGESTOGENS



# Endogenous progesterone

- Mostly produced by granulosa lutein cells
- Optimal role to allow for implantation
- Modulation of maternal immune system
- Suppression of inflammatory response

# natural progesterone

- Is rapidly metabolized after oral intake
- Ineffective in inducing a sufficient secretory transformation.

# synthetic progesterone derivatives

## The side-effects

- lipids
- the psyche

# micronization of progesterone

- Micronization particle of  $<10\ \mu\text{m}$
- increases the available surface area of the drug
- enhances the aqueous dissolution rate and intestinal absorption of progesterone.
- Suspension in oil and packaging in a gelatin capsule further enhance the intestinal absorption
- even higher doses of oral micronized progesterone have failed to induce sufficient secretory transformation.





# Dydrogesterone



- Pharmaceutical-grade progesterone and dydrogesterone are produced from the same starting material, diosgenin, from the Dioscorea plant: wild-yam



- Exposure to ultraviolet light ‘bends’ precursor material into a curved retro-steroid structure



- A retroprogesterone, a stereoisomer of progesterone, + additional double-bond between carbon 6 and 7

# Dydrogesterone

- high selectivity for the progesterone receptor minimizes unwanted effects
- Dydrogesterone versus oral micronized progesterone
  - Better oral bioavailability<sup>1,2</sup>
  - Requires a 10–20 times lower oral dose
- Selective for the progesterone receptor (and thus avoiding other receptor-related side effects)
- Vaginal micronized progesterone is also metabolized in the liver
- Oral micronized progesterone is associated with a risk of cholestasis in pregnancy

Transformation dose  
mg/day

Ovulation suppression dose  
mg/day

**p.o.**

**p.o.**

**progesterone**

**200- 300**

**300**

**Dydrogesterone**

**10- 20**

**>30**

**Medroxy progesterone**

**5- 10**

**10**

# i.m. application

disadvantages :

- pain at injection time
- swelling and redness and sterile abscess formation
- eosinophilic pneumonia
  - an allergic reaction toward the oil vehicle
  - life-threatening complication

# Subcutaneous progesterone

An alternative for women who want to avoid  
i.m. injections  
as well as the vaginal route

# Progesterone usage in ART

- Luteal phase support
- Blocking LH surge

# Progestin-primed ovarian stimulation (PPOS)

- Mechanism:  
Progesterone reduces GnRH's pulsatility from the hypothalamus, thus inhibiting the LH release associated with increased estradiol levels.
- In 2015, Kuang first used Medroxyprogesterone acetate (MPA) for LH suppression in COS.

# Progestin-primed ovarian stimulation (PPOS)

- Fixed regiment:  
started simultaneously with gonadotrophins and continued until the day of ovulation trigger
- Flexible regiment:  
started later in the cycle, based on leading follicle size or serum estradiol and/or LH levels
- Implies the freezing of all the embryos



# PPOS

- In DOR /advanced age had a more robust effect than GnRH-ant:
  - Antagonists are usually applied on Day 5 of the stimulation, when the leading follicle reached 12-14 mm or when the serum estradiol > 200 pg/ml  
→ LH surge may occur before the antagonist application (especially in advanced age / DOR).
  - GnRH- ant works on GnRH receptor directly but the endogenous estrogen-induced GnRH release is still preserved. PPOS can hinder estrogen's positive feedback on the hypothalamus.
- advantage of low incidence of OHSS (mechanism:??).



Luteal Phase Support (LPS)

# No gain from LPS

- Young women
- + normal ovarian reserve
- + normal BMI
- during natural cycle

# Why do we need luteal phase support in ART?

- egg retrieval >> multiple corpora lutea >> high levels of steroids >> negative feedback >> lower LH levels >> in the early luteal phase>> premature luteolysis
- Triggering by hCG or GnRH-a >> P level elevates
- “luteal gap” between hCG trigger and endogenous hCG of pregnancy:  
in GnRH-a cycles: inhibition of LH can last 2-3 weeks after the end of treatment.
- In cycles with GnRH-a trigger:
  - LH-FSH surge for final egg maturation is shorter than natural cycles → shorter life span of CL : 5 days.
  - GCs have lower level of LH receptors.
  - GCs have down-regulated expression of anti-apoptotic genes.
- FET / donor oocytes  
Artificially prepared endometrium with estradiol and progesterone >> suppressed ovulation>> lack of corpus luteum

# Luteal phase after GnRH-a triggering

The spontaneous LH surge:

- an ascending phase of approximately 4 h
- a peak plateau of 20 h
- a descending phase of 20 h

GnRH<sub>a</sub>-induced LH:

- shorter ascending phase of LH surge
- leads to a luteal phase with severe luteolysis

intensive luteal phase support is required (not later than 72 Hrs.) :

- i.m. progesterone injections
- hCG administration → risk of OHSS (even with 250 IU every 3 days) .

# LPS questions

- Timng
- Duration
- Rout



# OVARIAN STIMULATION FOR IVF/ICSI

Guideline of the European Society of Human Reproduction and Embryology

OCTOBER 2019  
ESHRE Reproductive Endocrinology Guideline Group



Cochrane Database of Systematic Reviews

## Luteal phase support for assisted reproduction cycles (Review)

van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M

van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M.  
Luteal phase support for assisted reproduction cycles.  
*Cochrane Database of Systematic Reviews* 2015, Issue 7. Art. No.: CD009154.  
DOI: [10.1002/14651858.CD009154.pub3](https://doi.org/10.1002/14651858.CD009154.pub3).

[www.cochranelibrary.com](http://www.cochranelibrary.com)

Luteal phase support for assisted reproduction cycles (Review)  
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

# GPP

# GDG

- Good Practice Point (GPP), which is the recommended best practice based on the clinical experience of the Guidelines Development Group (GDG).
- The level of recommendation is rather low



# Timing of initiation

start LPS during the window between the evening of the day of oocyte retrieval and day 3 post oocyte retrieval (GPP).

# Duration

P for LPS should continue at least until the day of the pregnancy test (GPP).

# The dosing of natural progesterone

Any non-oral routes for natural P can be used (GPP)

- 50 mg once daily for intramuscular progesterone
- 25 mg once daily for subcutaneous progesterone (prolutex)
- 90 mg once daily for vaginal progesterone gel
- 200 mg TDS for micronized vaginal progesterone in-oil capsules
- 100 mg TDS or BID for vag. P in starch supp (endometrin)
- 400 mg two times daily for vaginal pessary (cyclogest)

Dydrogesterone is probably recommended for luteal phase support (Conditional ⊕⊕⊕).

# ***Personalized luteal phase support***

- Neither the updated Cochrane meta-analysis on LPS, nor the ESHRE guidelines have included recommendations regarding patient monitoring during the luteal phase.